Merck's Tulisokibart Hits All Endpoints in Phase 3 Ulcerative Colitis Trial
MRK sits 49% above its 52-week low of $76.66 on elevated volume (2.8× avg).
Summary
Merck's investigational drug, Tulisokibart, achieved both primary and key secondary endpoints in its Phase 3 ATLAS-UC study for moderately to severely active ulcerative colitis. The trial identified no safety concerns, and Tulisokibart is the first anti-TL1A antibody to demonstrate clinical remission at 12 weeks in a Phase 3 UC trial. This successful outcome significantly de-risks the drug candidate and positions it as a potential new blockbuster, adding to Merck's robust pipeline successes seen recently with Enlicitide Decanoate and Keytruda.
At the time of this announcement, MRK was trading at $113.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $281.2B. The 52-week trading range was $76.66 to $125.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.